HutchMed

News

Hutchmed scores with drug for rare autoimmune disease

Hutchmed is preparing to file for approval of its drug for the rare disorder wAIHA in China, after chalking up a win in a pivotal phase 2/3 trial.

News

Hutchmed cashes in a Chinese JV to help fund its pipeline

Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.

News

Hutchmed files Takeda-partnered colorectal cancer drug in US

Chinese biotech Hutchmed has completed its rolling marketing application in the US for oral VEGF receptor inhibitor fruquintinib, which was licensed by Takeda for a hefty

News

Takeda grabs ex-China fruquintinib rights from Hutchmed

Chinese biotech Hutchmed's push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan's Takeda, including a hefty upfront fee of

News

Tagrisso paired with Hutchmed drug clears lung cancer test

EGFR inhibitors like AstraZeneca's Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations.

News

FDA says no to two more China-developed cancer drugs

The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what may be further evidence of a tough line taken by the regulator for drugs tested out

Hutchmed scores with drug for rare autoimmune disease

Hutchmed cashes in a Chinese JV to help fund its pipeline

Hutchmed files Takeda-partnered colorectal cancer drug in US

Takeda grabs ex-China fruquintinib rights from Hutchmed

Tagrisso paired with Hutchmed drug clears lung cancer test

FDA says no to two more China-developed cancer drugs

J&J jumps on the MFN pricing train

How to meet your physicians where they are online

HutchMed

Editor's Picks